Aims: To evaluate the glycaemic control achieved by prandial once-daily insulin glulisine injection timing adjustment, based on a continuous glucose monitoring sensor, in comparison to once-daily insulin glulisine injection before breakfast in patients with type 2 diabetes who are uncontrolled with once-daily basal insulin glargine. Results: A total of 121 patients were randomized to arm A (n = 61) or arm B (n = 60). There was no difference in mean HbA1c at week 24 between arms A and B (8.5% AE 1.2% vs 8.4% AE 1.0%; P = .66). The prandial insulin glulisine dosage for arm A and arm B was 9.3 and 10.1 units, respectively (P = .39). The frequency of hypoglycaemic events did not differ between study arms (36.1% vs 51.7%; P = .08).
1,2
The persistent advancing nature of type 2 diabetes, with progressive deterioration of pancreatic β-cell function, eventually requires insulin supplementation and intensification in an attempt to tackle a worsening glycaemic profile. 3, 4 Basal insulin, targeting elevated fasting plasma glucose (FPG), is often initiated in patients who fail to achieve target glycaemic control with oral anti-hyperglycaemic agents (OADs) and GLP-1 agonists; however, despite the addition of basal insulin, nearly 40% of such patients fail to achieve the recommended *Complete list of study investigators is available online (Table S3 , Appendix S1).
goal of HbA1c < 7%. 5, 6 For these patients, there has been growing acceptance of a strategy that progressively adds "bolus" rapid insulin to the basal insulin treatment, focusing on both FPG and postprandial plasma glucose (PPG). [7] [8] [9] The addition of bolus insulin is based on self-monitoring of blood glucose (SMBG) measurements and takes into account the patients' habits as they pertain to meal timing and composition and to their level of activity.
SMBG measurements can provide only intermittent snapshots of blood glucose levels, often missing hyperglycaemic or hypoglycaemic excursions; in contrast, a continuous glucose-monitoring (CGM) system provides information on day-to-day change in blood glucose levels and highlights the diverse contributions of FPG and PPG values at different HbA1c levels. Indeed, the optimal timing of PPG mea- In patients with type 2 diabetes who are uncontrolled with basal insulin plus OADs, a single bolus of rapid-acting insulin glulisine added to glargine demonstrates significant improvement in HbA1c levels and superior glycaemic control without an increase in the rates of hypoglycaemia, irrespective of the time of administration. 8, 9, 13 However, the impact of CGM on glycaemic control, when used to guide the timing of glulisine administration, is not well delineated in patients with type 2 diabetes. Therefore, we aimed to evaluate the effect of once-daily prandial glulisine treatment timing adjustment, based on CGM, in comparison to pre-breakfast once-daily prandial glulisine on glucose control in patients with type 2 diabetes who are uncontrolled with once-daily basal insulin. We designed a pilot study, assuming a difference of 0.5% in mean HbA1c in favour of the group of patients using CGM to determine the timing of insulin glulisine injection.
| RESEARCH DESIGN AND METHODS

| Study design and patient population
This was a 24-week, randomized, open-label, controlled, phase IV study, conducted at 11 sites across Israel. The study included an 8-week run-in period, followed by a 16-week period of intensified treatment. The study design and patient visits are provided online ( Figure S1 , Appendix S1).
The study (registered at clinicaltrial.gov: NCT01234597) was conducted in accordance with the ethical principles of the Declaration of Helsinki. Study protocol approval was obtained for each participating centre, and all patients provided written informed consent. with the exception of metformin and dipeptidyl peptidase-4 inhibitors, and patients were put on a basal insulin (insulin glargine) regimen, which was further titrated to achieve an FPG target of >70 to <100 mg/dL. Patients with HbA1c levels ≥7.5% and FPG < 130 mg/ dL at the end of the run-in period entered the randomization phase.
At the end of the run-in period, patients were screened according to randomization criteria (HbA1c and FPG). Generation of the random allocation sequence and actual randomization were performed by a statistical company (MediStat Ltd., Tel-Aviv, Israel). All eligible patients were randomized (1:1) at week 10 into 1 of the 2 study arms: Arm A patients were not connected to the CGM sensor, while arm B patients were connected to a blinded CGM sensor for 6 consecutive days and they returned 1 week after randomization. The insulin glargine dose was maintained constant from this time point.
Patients were reminded to examine their 7-point blood glucose profile on a particular day of the week before week 10 and record it in the diary.
| Intensified treatment period
From week 12 to week 24 (end of study), insulin glulisine was added to the fixed glargine dose. Patients in arm A received insulin glulisine 0 to 15 minutes before the first meal of the day, while patients in arm B received glulisine 0 to 15 minutes before the meal with the highest elevation in glucose level based on CGM data collected during the 6 days of monitoring. Patients in both groups were required to contact their physician before any dose adjustment. In both study arms, the initial dose of insulin glulisine was 6 units and the titration upwards or downwards was carried out to reach the target 2-hour postprandial blood glucose value of ≤135 mg/dL or to resolve recurrent hypoglycaemic events.
All patients were provided with diaries to record blood glucose levels, insulin doses, information related to hypoglycaemia and the 7-point blood glucose profile during the study period. Other information, such as demographic data, medical history, hypoglycaemic events and full diabetes-specific clinical history, was also collected.
| Primary and secondary outcome measures
The primary outcome was mean HbA1c at week 24 in both treatment arms. Secondary outcome measures included comparison of the rate of hypoglycaemic events and insulin glargine/insulin glulisine dose between the randomized groups. Hypoglycaemic events were defined as symptomatic (without measuring BG values) or moderate (symptoms of hypoglycaemia confirmed by BG values 55-70 mg/dL).
Severe hypoglycaemia was defined as measurable hypoglycaemia
with glucose values <55 mg/dL and/or the necessity of involvement of a third party in the treatment.
Other analyses included change in HbA1c and FPG levels from Week 8 to Week 24, glycaemic response rate (proportion of patients achieving HbA1c < 7%), 7-point blood glucose profile (fasting before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner and at bedtime) at 24 weeks, and change in 7-point glucose profile from Week 10 to Week 24 in both treatment arms.
| Statistical methods
| Determination of sample size
The rationale for sample size calculation is based on demonstration of a difference of at least 0.5% in HbA1c change from baseline between the treatments, with 80% power and 5% statistical significance. A sample size of 52 in each group would have 80% power to detect a difference in means of 0.50, assuming that the common standard deviation is 0.90 using a 2-group T-test with a 0.05 2-sided significance level. Analyses of efficacy data were performed using the intention-to-treat (ITT) population, which included all randomized patients. Additional analyses were performed using the per-protocol (PP) population, which included all patients who completed the study without major protocol violations. Safety evaluations were performed using the safety population that included all patients who had at least 1 dose of study medication. 3 | RESULTS
| Patient disposition and baseline characteristics
Between December 2012 and April 2015, 219 patients were screened for inclusion in the run-in phase. Of 219 patients screened, 121 patients were randomly assigned to the study treatments arms (arm A, n = 61; arm B, n = 60). Patient disposition is presented in Figure 1 . Baseline characteristics and demographics were similar between the study arms ( Table 1) . Patients were predominantly men (>55%) with a mean age of 63 years. The average duration of diabetes was 13.7 years and baseline weight was >80 kg. A majority of the randomized patients (>65%) in both arms were receiving insulin glargine at baseline.
| Glycaemic response
During the run-in phase, treatment with insulin glargine and subsequent dose titration resulted in a reduction of mean (SD) HbA1c from 24 in both groups (P = .021 for arm A and P = .004 for arm B). However, the change in FPG level at Week 24 between the 2 study arms was not significantly different (P = 0.51) ( Table 2) .
At the end of the study (Week 24), no significant difference was observed in patients achieving HbA1c < 7% between the study arms (arm A, 8.2% and arm B, 10.2%; P = .73). In arm B, 10 patients received glulisine before breakfast, 17 before lunch and 17 before dinner. The timing was not clear for the other 6 patients.
Mean 7-point blood glucose values did not differ between study arms (P > .05) at the end of the study (Figure 2) . No reduction was observed in 7-point plasma glucose levels in arm A ( Figure 3A) ; however, in arm B, a borderline reduction in plasma glucose levels was observed 2 hours after breakfast (P = .05) and a significant reduction in glucose levels was observed 2 hours after dinner (P = .04) ( Figure 3B ).
The change in 7-point blood glucose values from Week 10 to Week 24 for each glulisine injection-time group (morning/afternoon/ evening) was also analysed (Table S1 , Appendix S1). Glulisine injection before the meal was found to decrease 2-hour post-meal glucose values. Particularly, glulisine injection in the afternoon and evening showed a significant decrease in glucose values 2 hours after lunch (P = 0.02) and 2 hours after dinner (P = .04), respectively. However, this decrease was not significant when 3 injection-timing values were combined at each 7-point glucose-measurement timing.
| Insulin dose
At study entry, the mean daily insulin glargine dose for all participants was 35 units (arm A, 37 and arm B, 33; P = .26), which increased to a mean of 39 units (arm A, 41 and arm B, 37; P = .24) at the end of the run-in phase (Week 8). The prandial insulin glulisine dose for arms A and B was 9.3 AE 4.5 units and 10.1 AE 4.6 units, respectively, at the end of the study (Week 24). There was no significant difference in insulin glulisine dose at week 24 between study arms (P = .39) ( Table 2 ).
| Hypoglycaemic events
The frequency of hypoglycaemic events during the study period was not statistically different between study arms (36.1% for arm A vs 51.7% for arm B; P = .08 using chi-Square test and P = .11 using logistic regression) ( 
| Safety and tolerability
AEs were equally distributed between the 2 treatment groups. Overall, 40 AEs were reported in arm A and 46 in arm B. The most frequently reported system organ classes were "general disorders and administration site conditions" and "gastrointestinal disorders" in both treatment groups. The most common AEs by preferred term were dyspepsia, chest pain, asthenia, dizziness, headache, diabetic neuropathy, abdominal pain, tooth disorder, hypoglycaemia, back pain, chronic obstructive pulmonary disease and dyspnea. During the study, no deaths, no severe hypoglycaemic events, and no new safety signals were reported in the study population. Most AEs were mild in intensity and were unrelated to the study drug. A tabulated summary of adverse events can be found online (Table S2 , Appendix S1). Data are presented as mean AE SD unless otherwise indicated. * by chi-square test; ** by logistic regression. The PPG exhibits a closer association with HbA1c and has a stronger correlation with development of diabetes complications than FPG. [19] [20] [21] The primary approach in reducing glycaemic load is addition and up-titrating of long-acting basal insulin injection, which affects both pre-and postprandial glucose. However, PPG control is necessary for patients who are close to, but not at, target (HbA1c < 7%), for those using high doses of basal insulin without success (>0.7 U/kg) or those who are at increased risk of nocturnal hypoglycaemia which prevents further titration of basal insulin doses. 22, 23 This can be addressed by administration of a rapid-acting insulin analogue at mealtime, producing a rapid and short insulin spike to control the PPG elevation.
In daily practice, the challenges faced with insulin intensification may benefit from the use of a CGM sensor, which can guide clinicians in optimizing multiple insulin regimens while avoiding hypoglycaemia. 24, 25 Use of a CGM sensor has been evident in optimizing insulin therapy in type 1 diabetes. [26] [27] [28] [29] In this study, the significance of CGM in optimizing insulin therapy in patients with type 2 diabetes who are uncontrolled with basal insulin and OADs was evaluated. The rational for empiric pre-breakfast bolus injection, as the first step in intensification of a basal insulin regimen, is that, during the morning, the probability of glucose excursions is highest, which may be associated, in part, with the relatively higher levels of insulin resistance driven by the diurnal secretion of cortisol and growth hormone. 31, 32 Therefore, glulisine injection just prior to breakfast may be a simple way to improve glycaemic control. The results of the present study are in concordance with those of the OPAL study 8 in which adding the bolus dose at breakfast achieved results similar to those achieved with adding the bolus dose before the largest meal (by anamnesis and not using CGM).
The lack of a control group that received only basal insulin could represent a limitation of our study. However, during the run-in phase, despite receiving basal insulin, many patients did not achieve target
HbA1c, but after addition of glulisine in the randomized phase, they exhibited a decrease in HbA1c. Hence, the glycaemic improvement can be attributed to the glulisine injection.
In conclusion, using CGM for identifying the meal with highest glucose excursion and adjusting the timing of prandial insulin glulisine administration accordingly, did not show any advantage in terms of glycaemic outcome or safety in our patients. However, it may be considered for patients in whom a specific meal is suspected to contribute considerably to the HbA1c level.
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